Abstract

BackgroundThere is a strong need to improve medication adherence (MA) for individuals with hypertension in order to reduce long-term hospitalization costs. We believe this can be achieved through an artificial intelligence agent that helps the patient in understanding key individual adherence risk factors and designing an appropriate intervention plan. The incidence of hypertension in Sweden is estimated at approximately 27%. Although blood pressure control has increased in Sweden, barely half of the treated patients achieved adequate blood pressure levels. It is a major risk factor for coronary heart disease and stroke as well as heart failure. MA is a key factor for good clinical outcomes in persons with hypertension.ObjectiveThe overall aim of this study is to design, develop, test, and evaluate an adaptive digital intervention called iMedA, delivered via a mobile app to improve MA, self-care management, and blood pressure control for persons with hypertension.MethodsThe study design is an interrupted time series. We will collect data on a daily basis, 14 days before, during 6 months of delivering digital interventions through the mobile app, and 14 days after. The effect will be analyzed using segmented regression analysis. The participants will be recruited in Region Halland, Sweden. The design of the digital interventions follows the just-in-time adaptive intervention framework. The primary (distal) outcome is MA, and the secondary outcome is blood pressure. The design of the digital intervention is developed based on a needs assessment process including a systematic review, focus group interviews, and a pilot study, before conducting the longitudinal interrupted time series study.ResultsThe focus groups of persons with hypertension have been conducted to perform the needs assessment in a Swedish context. The design and development of digital interventions are in progress, and the interventions are planned to be ready in November 2020. Then, the 2-week pilot study for usability evaluation will start, and the interrupted time series study, which we plan to start in February 2021, will follow it.ConclusionsWe hypothesize that iMedA will improve medication adherence and self-care management. This study could illustrate how self-care management tools can be an additional (digital) treatment support to a clinical one without increasing burden on health care staff.Trial RegistrationClinicalTrials.gov NCT04413500; https://clinicaltrials.gov/ct2/show/NCT04413500International Registered Report Identifier (IRRID)DERR1-10.2196/24494

Highlights

  • OverviewHypertension is a common, dangerous, and treatable but undertreated condition worldwide and has a prevalence of approximately 30% in adults [1]

  • The design of the digital intervention is developed based on a needs assessment process including a systematic review, focus group interviews, and a pilot study, before conducting the longitudinal interrupted time series study

  • The results show that digital interventions were effective in that regard, and the main targeted behaviors to change were lifestyle management, medication intake, self-measurement, and patient-provider interaction

Read more

Summary

Introduction

OverviewHypertension is a common, dangerous, and treatable but undertreated condition worldwide and has a prevalence of approximately 30% in adults [1]. Blood pressure (BP) control has increased in Sweden, barely half of the treated patients achieved adequate BP levels [6]. There is a strong need to improve medication adherence (MA) for individuals with hypertension in order to reduce long-term hospitalization costs We believe this can be achieved through an artificial intelligence agent that helps the patient in understanding key individual adherence risk factors and designing an appropriate intervention plan. Blood pressure control has increased in Sweden, barely half of the treated patients achieved adequate blood pressure levels It is a major risk factor for coronary heart disease and stroke as well as heart failure. Objective: The overall aim of this study is to design, develop, test, and evaluate an adaptive digital intervention called iMedA, delivered via a mobile app to improve MA, self-care management, and blood pressure control for persons with hypertension. Trial Registration: ClinicalTrials.gov NCT04413500; https://clinicaltrials.gov/ct2/show/NCT04413500 International Registered Report Identifier (IRRID): DERR1-10.2196/24494

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call